by Madaline Spencer | May 1, 2024
Michael Hayden, PhD, CEO of Prilenia, discusses recent clinical trials testing pridopidine for the treatment of amyotrophic lateral sclerosis (ALS) and Huntington’s disease. ALS, also referred to as Lou Gehrig’s disease, is a motor neuron disease...
by Madaline Spencer | Apr 29, 2024
The U.S. Food and Drug Administration (FDA) has approved Xolremdi (mavorixafor), the first therapy to receive approval for the treatment of persons with WHIM syndrome. WHIM syndrome is an acronym for a rare immunodeficiency disorder with each letter...
by Madaline Spencer | Apr 25, 2024
Michael Levy, MD, PhD, Massachusetts General Hospital and Harvard Medical School, discusses neuromyelitis optica spectrum disorder (NMOSD) and the ongoing trial for a new app that can better monitor patients with NMOSD. NMOSD is an autoimmune disorder...
by Madaline Spencer | Apr 23, 2024
Tuan Vu, MD, Professor of Neurology at University of South Florida, discusses myasthenia gravis and results from the Phase 3 CHAMPION clinical trial, testing the safety and efficacy of ravulizumab. Myasthenia gravis (MG) is a chronic autoimmune...
by Madaline Spencer | Apr 19, 2024
The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug application (IND) for SPG601 for the treatment of Fragile X Syndrome (FXS). Fragile X syndrome is a genetic condition involving changes in part of the X chromosome. FXS...
